BioRestorative to present Phase 2 BRTX-100 data at spine symposium; Q3 results call Nov 13

BioRestorative Therapies, Inc.

Additional preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented on Nov 13, 2024.
Presentation at Orthopaedic Research Society/Philadelphia Spine Research Society 7th International Spine Research Symposium, Nov 10-14.
Company will host webcasted conference call Nov 13 at 4:30pm ET to review data, Q3 2024 financial results, and provide business update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.